AcelRx Pharmaceuticals, Inc. (ACRX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.7199 |
| Open | 0.7180 |
| Bid | 0.6500 x 3000 |
| Ask | 0.7025 x 900 |
| Day's Range | 0.6700 - 0.7180 |
| 52 Week Range | 0.5700 - 7.6000 |
| Volume | |
| Avg. Volume | 227,226 |
| Market Cap | 5.739M |
| Beta (5Y Monthly) | 0.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4740 |
| Earnings Date | May 15, 2023 - May 19, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 80.00 |
- PR Newswire
AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release full year and fourth quarter financial results for 2022 after the market close on Thursday, March 30, 2023. Thereafter, AcelRx management will host a live webcast and conference call at 4:30 p.m. Eastern Daylight Time/1:30 p.m. Pacific Daylight Time on March 30, 2023
- PR Newswire
AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the divestment of its FDA-approved drug, DSUVIA® to Alora Pharmaceuticals (Alora). The agreement allows AcelRx to participate in the long-term value expected to be created by Alora as they expand the commercialization of DSUVIA.
- PR Newswire
AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a report arising from a series of rhinology procedures successfully performed using sufentanil sublingual tablet 30 mcg (SST; DSUVIA) in Otolaryngology Case Reports. The study was lead-authored by otolaryngologist Dr. Ashley Sikand and entitled "Evaluation of
